Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or pal...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Breast Cancer Res
Glavni autori: Rossi, Lorenzo, Biagioni, Chiara, McCartney, Amelia, Migliaccio, Ilenia, Curigliano, Giuseppe, Sanna, Giuseppina, Moretti, Erica, Minisini, Alessandro M., Cinieri, Saverio, Tondini, Carlo, Arpino, Grazia, Bernardo, Antonio, Martignetti, Angelo, Risi, Emanuela, Pestrin, Marta, Boni, Luca, Benelli, Matteo, Biganzoli, Laura, Di Leo, Angelo, Malorni, Luca
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Short Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6542028/
https://ncbi.nlm.nih.gov/pubmed/31142370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-019-1149-5
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items